Neogen (NASDAQ:NEOG) Director William T. Boehm sold 500 shares of the stock in a transaction on Wednesday, April 18th. The shares were sold at an average price of $69.84, for a total value of $34,920.00. Following the completion of the transaction, the director now directly owns 10,480 shares in the company, valued at approximately $731,923.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ NEOG traded down $0.01 during trading hours on Friday, hitting $69.88. The company had a trading volume of 109,197 shares, compared to its average volume of 207,079. Neogen has a 1-year low of $45.01 and a 1-year high of $70.41. The company has a market capitalization of $3,605.14, a PE ratio of 81.26, a P/E/G ratio of 4.13 and a beta of 1.27.
Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Thursday, March 22nd. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.08. Neogen had a net margin of 14.82% and a return on equity of 11.49%. The company had revenue of $95.90 million during the quarter, compared to the consensus estimate of $97.93 million. During the same quarter in the prior year, the firm posted $0.27 earnings per share. Neogen’s revenue for the quarter was up 8.5% on a year-over-year basis. sell-side analysts anticipate that Neogen will post 1.13 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fairfield Bush & CO. boosted its stake in Neogen by 7.2% in the fourth quarter. Fairfield Bush & CO. now owns 92,411 shares of the company’s stock valued at $7,597,000 after acquiring an additional 6,171 shares in the last quarter. Xact Kapitalforvaltning AB acquired a new position in Neogen in the fourth quarter valued at $332,000. Envestnet Asset Management Inc. boosted its stake in Neogen by 25.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 50,169 shares of the company’s stock valued at $4,124,000 after acquiring an additional 10,288 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Neogen in the fourth quarter valued at $1,466,000. Finally, Metropolitan Life Insurance Co. NY acquired a new position in Neogen in the fourth quarter valued at $965,000. Institutional investors own 68.14% of the company’s stock.
NEOG has been the topic of several recent analyst reports. Zacks Investment Research raised Neogen from a “hold” rating to a “buy” rating and set a $74.00 target price on the stock in a report on Wednesday, March 28th. ValuEngine raised Neogen from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub raised Neogen from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Roth Capital set a $62.00 target price on Neogen and gave the company a “hold” rating in a report on Thursday, January 4th. Finally, Stephens reissued a “hold” rating and issued a $62.00 target price on shares of Neogen in a report on Wednesday, January 10th. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Neogen has an average rating of “Hold” and a consensus price target of $65.25.
COPYRIGHT VIOLATION WARNING: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2018/04/21/neogen-neog-director-william-t-boehm-sells-500-shares.html.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.